Viking Therapeutics
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Careers
  • Pipeline
    • Overview
    • Metabolic Disease Program
    • Rare Disease Program
    • Musculoskeletal Program
    • Other Pipeline Programs
  • Investors & Media
    • Overview
    • Stock Information
    • News & Events
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • Corporate Presentation
  • Contact

    SEC Filings

    Investors

    • Overview
    • Stock Information
    • News & Events
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • Corporate Presentation

    NASDAQVKTX
    YearTrailing 12-MonthsCalendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2017Calendar Year 2016Calendar Year 2015Calendar Year 2014
    ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
    FormDescriptionDateFormat
    DEFA14AAdditional proxy soliciting materials - definitiveApr 6, 2018Open Additional proxy soliciting materials - definitive in HTML.Open Additional proxy soliciting materials - definitive in DOC file.Open Additional proxy soliciting materials - definitive in PDF file.Open Additional proxy soliciting materials - definitive in XLS file.
    DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 6, 2018Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in HTML.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in DOC file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in PDF file.Open Official notification to shareholders of matters to be brought to a vote ("Proxy") in XLS file.

     

     

    viking therapeutics

    About

    Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.

    Contact

    General Information
    Business Development
    ©2022 Viking Therapeutics
    Terms of Use
    Privacy Policy